Simone Lubrano

Postdoc in the @SilvioGutkind Lab @UCSDCancer 🇺🇸 Marie-Curie Fellow 🇪🇺🇮🇹

[GutkindLab @SilvioGutkind]

Our Gutkind lab featured in the newspaper in Livorno, Italy, thanks to former postdoc @SimoneLubrano , for his Early Career Award from the Society for Melanoma Research @SocietyMelanoma! Grazie Simone!

[Melanoma Research Foundation @CureMelanoma]

We are proud to recognize two outstanding researchers honored at the recent Society for Melanoma Research (SMR) International Congress.

The Christopher J. Marshall Award was presented to Dr. Simone Lubrano, PhD (University of Pisa, Italy and UCSF) for his recent research achievements and publications including “FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma,” recently published in Cancer Cell. https://t.co/PKQmwnWAYU

The Young Investigator Award was awarded to Dr. Joanna Poźniak, PhD (VIB-KU Leuven, Laboratory for Molecular Cancer Biology, Belgium) for her research accomplishments and Cancer Discovery publication “Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-excluded Phenotype”. https://t.co/ycTYCjKXgA

Both awards highlight the MRF’s commitment to melanoma research advancements and supporting the next generation of scientific leaders driving innovation and progress in the field.

Learn more about all MRF funded research here: https://t.co/bjmC4Uzxe3

Photo 1: Dr. Joanna Pozniak, PhD, with Bonnie Teng, PhD, Kyleigh LiPira and Dr. Liz Patton, PhD.

Photo 2: Dr. Simone Lubrano, PhD, with Bonnie Teng, PhD, Kyleigh LiPira and Dr. Liz Patton, PhD.

[Simone Lubrano @SimoneLubrano]

Grateful and proud to receive the Christopher J. Marshall Award from the @SocietyMelanoma supported by @CureMelanoma recognizing early-career scientists driving discoveries in melanoma biology. A wonderful honor and motivation to keep pushing forward. #Melanoma #Research #SMR

[UC San Diego Health Moores Cancer Center @UCSDCancer]

Melanoma resists BRAF-targeted treatments, but combining avutometinib with FAK inhibitors may help overcome it.

MCC's AD of Basic Science, @SilvioGutkind, explores this in a recent @Cancer_Cell publication: https://t.co/MAQymxulvZ.

[Mar de Miguel @MarJungle]

✍️#Melanoma Combination therapy overcomes treatment resistance in #melanoma
📢Interview with @SilvioGutkind @SimoneLubrano (UC San Diego).
👉https://t.co/R3fhXlC2oq Researchers uncover a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation.

[Cancer Cell @Cancer_Cell]

Online Now: FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma https://t.co/GKYwhIYLgF

[Simone Lubrano @SimoneLubrano]

Special thanks to @RDanielCervant1 @Farhoud916 🧑‍🔬

[Simone Lubrano @SimoneLubrano]

Thrilled to share that our paper is now out in @Cancer_Cell ! 🚀 A true @SilvioGutkind team effort. Huge thanks to all collaborators, especially Silvio for his invaluable support and all our collaborator in particular @AndrewEAplin @HolmenLab
https://t.co/ofaurtc0sm

[Simone Lubrano @SimoneLubrano]

@raimondifranc Congratulations Francesco! 👏👏

[Simone Lubrano @SimoneLubrano]

I invite you to attend the Seminar I will be giving on Thursday, December 12 at 11:30 a.m. at the Scuola Normale Superiore, Pisa, on our latest Research on Strategies to Overcome Therapy Resistance in Cutaneous Melanoma.

[Simone Lubrano @SimoneLubrano]

It’s been such an honor to present at the main session of the SMR @SocietyMelanoma Conference in New Orleans 🇺🇸, to be recognized for one of the top oral trainee presentations, and to discuss our results with some of the world’s leading Melanoma Scientists. #Melanoma #Resistance

[Daniela Robles @daniela-oaks.bsky.social @daniela_oaks]

Now, @SimoneLubrano from @SilvioGutkind's lab @UCSDCancer is telling us about drug combinations to overcome resistance to BRAF/MEK inhibitors and immunotherapy in #melanoma #TraineeMeeting @SocietyMelanoma

[Simone Lubrano @SimoneLubrano]

All students of the PhD course in Science of Drug and Bioactive Substance are welcome to attend the seminar. Thank you!

[Simone Lubrano @SimoneLubrano]

Thanks @SilvioGutkind for this amazing experience, such a great environment, and wonderful/talented scientists. Looking forward to continuing our collaboration!

[GutkindLab @SilvioGutkind]

Farewell cake for Sally and Simone @SimoneLubrano ! Many many thanks for your contributions to our lab! It was a privilege working with you! Celebrating your accomplishments, and your many amazing discoveries to come. Thanks! Cheers!

[Fondazione AIRC per la ricerca sul cancro @AIRC_it]

#InViaggioconlaRicerca🇺🇲: grazie a una borsa iCARE-2 sostenuta da AIRC e dalla UE, Simone Lubrano si trova al Moores Cancer Center dell’Università della California a San Diego per studiare il melanoma uveale, un tumore dell'occhio ancora poco curabile
➡ https://t.co/UddbETRjjN